Voriconazole is a triazole antifungal that has a broad spectrum of activity against yeast, molds, and dimorphic fungi. Voriconazole is currently recommended as the first-line therapy for patients with invasive Aspergillus infection and can also be utilized to treat patients with other life-threatening systemic mycoses. Since voriconazole has limited water solubility, the intravenous (IV) voriconazole formulation includes the vehicle Sulfobutyl Beta Cyclodextrin Sodiu (SBECD).

There have a study demonstrates that SBECD is readily removed by CVVH allowing for the use of IV voriconazole without significant SBECD accumulation. CVVH was responsible for greater than 86% of the total systemic SBECD clearance and this corresponded to a similar rate of SBECD recovery in the effluent fluid. The finding that SBECD is removed by extracorporeal filters is similar to previous studies of intermittent hemodialysis modalities.

CVVH effectively removed SBECD at a rate similar to the ultrafiltration rate. Voriconazole clearance by CVVH was not clinically significant. Standard dosages of IV voriconazole can be utilized in patients undergoing CVVH without significant risk of SBECD accumulation.